Sudhir Agrawal

• Explore the chemistry behind circularised antisense oligonucleotides and understand how these designs differ from conventional linear gapmer ASOs
• Evaluate whether circularisation can meaningfully improve stability, pharmacokinetics and therapeutic durability compared with existing antisense approaches
• Gain deeper technical insight into an emerging chemistry platform that has rapidly gained industry attention but remains relatively unexplored from a development perspective

Small activating RNA remains one of the most debated areas within RNA therapeutics, with supporters highlighting its potential for durable gene activation whilst critics question its maturity, scalability and clinical translation. This live hot seat will challenge assumptions around saRNA development, bringing opposing perspectives together to examine where science stands today and what needs to happen for broader adoption

• Watch a controversial and evolving technology be critically examined through a live cross-examination rather than a traditional presentation format
• Explore the key scientific and development questions around saRNA, including delivery, durability, specificity and clinical readiness
• Gain a balanced perspective on whether saRNA represents a future therapeutic opportunity or remains an area requiring further validation before significant investment